Aadi Bioscience appoints Emma Reeve to Board, changes auditor to BDO after reverse merger

Whitehawk Therapeutics, Inc.

Emma Reeve appointed Class III director and Audit Committee Chair, effective Sept 8, 2021.
Reeve brings experience from Constellation Pharmaceuticals (CFO, oversaw $1.7B sale) and board seats at PTC Therapeutics, Editas Medicine.
Auditor changed: Ernst & Young dismissed, BDO engaged as independent auditor following reverse merger with Old Aadi; no disagreements or reportable events.
Company highlights upcoming PDUFA target action date of Nov 26, 2021 for FYARRO (nab-sirolimus) in PEComa.

item 4.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Emma Reeve

Class III Director

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2021-09-08
Filed: September 13, 2021, 7:59 PM ET

On September 8, 2021, Emma Reeve was appointed a Class III director by the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Emma Reeve was appointed as Class III Director at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On September 8, 2021, Emma Reeve was appointed a Class III director by the Board.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-270953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.